



SUVEN Life Sciences

Communication to investors
Dec 2011

31-Jan-12

2011-12 32 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW

Quarter 3 – Dec 2011



• Growth in revenue	56.80%
• Growth in PAT	15.61%
• Growth in EBIDTA	168.26%
• Growth in Pre-R&D EBIDTA	24.57%
• Increase in R&D costs	9.91%
• R&D cost on revenue	17.09%

FINANCIAL QUICK VIEW

Period ending – Dec 2011



• Growth in revenue	37.53%
• Growth in PAT	4.61%
• Growth in EBIDTA	33.62%
• Growth in Pre-R&D EBIDTA	13.25%
• Increase in R&D costs	5.77%
• R&D cost on revenue	17.16%


MAJOR PROFITABILITY RATIOS



	Q3 Dec 11	Q3 Dec 10	PE Dec 11	PE Dec 10
PAT to Income	2.58%	3.50%	4.99%	6.56%
EBIDTA to Income	4.26%	2.49%	7.96%	8.19%
Cash Flow to Income	5.33%	7.80%	7.87%	10.44%
Pre-R&D EBITDA to Income	21.35%	26.87%	25.12%	30.50%



INCOME COMPARISON




31-Jan-12

2011-12 Q3 results



PROFIT COMPARISON




PAT for qtr ending Dec11 is after provision for MTM of Rs. 66.08 Million towards forward contracts due to exchange fluctuation

31-Jan-12

2011-12 Q3 results



EBIDTA COMPARISON




31-Jan-12

2011-12 Q3 results



R & D – EXPENDITURE




31-Jan-12

2011-12 Q3 results



PRE-R&D EBIDTA




31-Jan-12

2011-12 Q3 results



PRE-R&D CASHFLOW



31-Jan-12

2011-12 Q3 results



Updates for the quarter

- During the quarter there were major qualitative achievements with the grant of 4 product patents to Suven's drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.